A field guide to BPC-157The criteria
PRODUCT / CARE / COMMITMENT
Open the provider file

Research explained

BPC-157 in dopamine and nitric-oxide behavioral challenges

These models do not establish an antipsychotic effect or safe medication combinations in people.

On this page

Read the experiment

The finding and its boundary

The investigators reported modifications of several drug-induced behavioral responses. These models do not establish an antipsychotic effect or safe medication combinations in people.

Pentadecapeptide BPC 157 counteracts L-NAME-induced catalepsy. BPC 157, L-NAME, L-arginine, NO-relation, in the suited rat acute and chronic models resembling 'positive-like' symptoms of schizophrenia.

Experiment
Experimental animal investigation with the intervention and outcomes specified in the indexed abstract.
Study system
Rats receiving acute and repeated pharmacologic challenges
Measured outcome
Motor activity, sensitization and catalepsy measures
Reported result
The investigators reported modifications of several drug-induced behavioral responses.
What this cannot establish
These models do not establish an antipsychotic effect or safe medication combinations in people.
Open the primary paper

What was actually tested

Rats receiving acute and repeated pharmacologic challenges. The investigators measured motor activity, sensitization and catalepsy measures. The investigators reported modifications of several drug-induced behavioral responses.

The detail that changes the takeaway

A motor test is an operational measure, not a direct readout of hallucinations or a patient's lived symptoms. Several challenge drugs can affect movement for different reasons. The authors' pathway interpretation needs to remain separate from any proposed clinical psychiatric use.

How far the result travels

These models do not establish an antipsychotic effect or safe medication combinations in people.

A useful comparison

Sphincter pressure after dopamine-related agents examines manometric pressures in lower-esophageal and pyloric sphincters. Here, the measured endpoint was motor activity, sensitization and catalepsy measures. Those outcomes belong to separate experiments; one is not a replication or a human confirmation of the other. Compare that distinction with the Can one BPC-157 study support the product in front of you? appraisal.

References & product documents

The evidence and service information used here.

  1. BPC-157 in dopamine and nitric-oxide behavioral challenges — original indexed research

Next in the field guide

The provider file
  1. 01

    Sphincter pressure after dopamine-related agents

    The result is not evidence that BPC-157 prevents medication-related reflux in patients.

  2. 02

    Can one BPC-157 study support the product in front of you?

    Match the claim, ingredient, route and outcome. A relevant paper can still leave the central purchasing question unanswered.

  3. 03

    Vascular outcomes after dopamine-related drug challenges

    The experimental drug challenges do not establish safety for routine psychiatric treatment combinations.

Before you leave

One more option to compare.

Another provider review

We may earn a commission from qualifying provider referrals. Affiliate placements are labeled Partner. How we are funded

Continue to your choiceRead another review